Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10361958" target="_blank" >RIV/00216208:11110/17:10361958 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/17:10361958
Result on the web
<a href="http://dx.doi.org/10.1177/1756285616671887" target="_blank" >http://dx.doi.org/10.1177/1756285616671887</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/1756285616671887" target="_blank" >10.1177/1756285616671887</a>
Alternative languages
Result language
angličtina
Original language name
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis
Original language description
Daclizumab is a humanized monoclonal antibody that binds to the a subunit (CD25) of the interleukin- 2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrastenhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon beta 1a. This review summarizes the development of and clinical experience with daclizumab in MS.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Therapeutic Advances in Neurological Disorders
ISSN
1756-2856
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
67-75
UT code for WoS article
000396377100006
EID of the result in the Scopus database
2-s2.0-85008482394